藍特光學(688127.SH):擬2.1億元投建年產5100萬件玻璃非球面透鏡技改項目
格隆匯8月30日丨藍特光學(688127.SH)公佈,2022年8月29日,公司第四屆董事會第十五次會議審議通過了《關於擬投資建設"年產5100萬件玻璃非球面透鏡技改項目"的議案》,本項目改造公司現有約4,500平方米廠房,其中新增加3,700平方米無塵車間。計劃總投入21,000萬元,購置超精密非球面加工機、真空鍍膜機、模壓機自動供給裝置、模壓機、鍍膜機冷卻系統、CNC精雕機、超聲波清洗機、小型自動磨邊機、離心乾燥機、非球面箱式退火爐等生產設備、各類輔助設備及檢測儀器等,形成年產5,100萬件玻璃非球面透鏡的生產能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.